Final answer:
Maropitant (Cerenia) is an NK1 receptor antagonist that prevents vomiting in animals; however, it is not related to the antiproliferative effects of Src-kinase inhibitors mentioned in the reference, which are studied in cancer cell inhibition.
Step-by-step explanation:
Maropitant (Cerenia) functions as a neurokinin-1 (NK1) receptor antagonist, which is effective in preventing vomiting. Its mechanism of action (MOA) involves blocking the binding of substance P—a neurotransmitter involved in emesis—to NK1 receptors in the brain's vomiting center. The effect of Maropitant is the prevention of acute vomiting in dogs and cats and the prevention of motion sickness in dogs.
The antiproliferative and pro-apoptotic effects mentioned in the reference provided are associated with novel Src-kinase inhibitors, which are different from Maropitant's therapeutic uses. Src-kinase inhibitors have been studied for their potential to inhibit the growth of cancer cells, such as in the case of human neuroblastoma cells as indicated by the reference. These inhibitors work by blocking the Src kinase enzyme, which is involved in the signaling pathways that can lead to cell proliferation and survival of cancer cells.